Ask My Investor AI
Public company · NYSEPublished company research
CAH

Ticker/exchange (NYSE: CAH), Dublin, Ohio HQ and Ohio incorporation corroborated via the issuer newsroom; legal name CARDINAL HEALTH INC, CIK 0000721371 and June 30 fiscal year-end taken from the SEC-verified FY2025 10-K metadata in the packet. Direct SEC EDGAR HTML/JSON fetch returned HTTP 403, so filing figures reuse the packet's prior_batch rather than independent re-extraction; the seed ticker hint CAH is correct.

Cardinal Health, Inc.

Cardinal Health combines a defensive pharmaceutical-distribution business with a direct Nuclear and Precision Health Solutions operation. Q3 FY2026 revenue was $60.9B, while the aggregated Other category containing NPHS produced $1.7B of revenue and $179M of segment profit. The company also announced expanded cGMP Actinium-225 capacity. These facts establish capability and a growing operating category, but NPHS economics are not separately disclosed and current valuation remains unavailable, so the subject stays NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
CAH
Exchange
NYSE
HQ
United States
Currency
USD
SEC CIK
0000721371
Investment case

How this company captures the theme economics

Competitive position

A US 'Big 3' drug distributor alongside McKesson and Cencora, collectively intermediating the large majority of US pharmaceutical distribution; scale, purchasing power and generic sourcing are the moat. In nuclear medicine it operates the largest radiopharmaceutical network in the United States and describes itself as the only national US source for both PET and SPECT radiopharmaceuticals.

Scarce assets

A national nuclear pharmacy and manufacturing footprint (~130 nuclear pharmacies including 3 central pharmacies and 30+ PET/manufacturing sites) whose decay-constrained, time-critical cold-chain logistics are extremely hard to replicate; a Center for Theranostics Advancement in Indianapolis with expanding cyclotron capacity and Actinium-225 production; and deep manufacturer, payer and provider relationships across ~8,800 nuclear-medicine customers.

Products, segments, and customers

Two reportable segments: Pharmaceutical and Specialty Solutions (~$204.6B FY2025 revenue) and Global Medical Products and Distribution / GMPD (~$12.6B). Remaining businesses sit in 'Other' (~$5.4B revenue, ~$516M segment profit FY2025): Nuclear and Precision Health Solutions (NPHS), at-Home Solutions and OptiFreight Logistics. NPHS operates nuclear pharmacies and manufacturing facilities that manufacture, prepare and deliver radiopharmaceuticals for imaging and theranostics, contract-manufactures Xofigo, and owns North American rights to Lymphoseek. Customers span pharma innovators, hospital nuclear-medicine and cardiology, oncology and urology clinics.

Theme capture

It captures medical-isotope and radiopharmaceutical-logistics economics through the last-mile bottleneck: short-half-life doses must be compounded and delivered locally the same day, which favors the densest national dispensing network. NPHS dispenses roughly 12 million patient-specific doses annually and is investing $150M+ to expand cyclotron capacity across 11 US markets and grow Ac-225 theranostics supply, positioning it for a nuclear-medicine market expected to grow sharply through 2030.

Conditions

What must be true

  1. Core pharmaceutical distribution volumes and generic economics remain stable and specialty/GLP-1 growth persists, sustaining Pharmaceutical segment profit growth.
  2. The $150M+ NPHS cyclotron and theranostics investment converts into durable 'Other'-segment profit growth as theranostics and radioligand therapies scale.
  3. GMPD's margin recovery continues rather than reverting under tariff, inflation or medical-product pricing pressure.
  4. Opioid settlement and other legal cash outflows stay within reserved amounts without material new liabilities.

Identifiable catalysts

  • Investor Day 2025 raised the long-term 'Other'-segment (incl. NPHS) normalized profit-growth target to ~10%, with FY2025 profit-growth guidance of 19-21%.
  • Announced expansion of Actinium-225 production at the Center for Theranostics Advancement (2026), increasing supply for investigational and future commercial radioligand therapies.
  • New theranostic/radioligand drug approvals driving isotope dose demand, plus ramp of recent specialty acquisitions (e.g., GI Alliance).
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Nuclear pharmacy compounding and last-mile radiopharmaceutical distribution — the dispensing and logistics bottleneck between isotope producers / drug innovators and imaging and therapy providers.

Medical isotopes and radiopharmaceutical logistics

High and direct at the manufacturing, nuclear-pharmacy and last-mile logistics layers, but financially aggregated. Official Q3 FY2026 reporting identifies NPHS as a contributor to Other-category growth, and the April 2026 capacity release documents a new high-capacity cGMP Actinium-225 production line for investigational and future commercial therapies.

Evidence
The FY2025 10-K identifies NPHS and radiopharmaceutical operations; the Q3 FY2026 release reports Other-category revenue of $1.7B and profit of $179M with NPHS among the growth contributors; the Ac-225 release directly supports production capability. Discrete NPHS revenue, profit and Ac-225 utilization remain undisclosed.
Materiality
disclosed — The issuer's FY2025 10-K explicitly names the Nuclear and Precision Health Solutions operating segment and its radiopharmaceutical operations and product lines (Xofigo, Lymphoseek), so the exposure itself is disclosed, not merely inferred; however discrete dollar materiality for the isotope business is not broken out (aggregated within the 'Other' category), so the exposure is named and qualitatively disclosed but not separately quantified.
Financial evidence

Official SEC filing evidence

Reference period: FY2025 and Q3 FY2026.

  • Revenue$60.9B; +11% year over year
    Q3 FY2026[1]
  • Other-category revenue$1.7B; +31% year over year; includes NPHS, at-Home Solutions and OptiFreight Logistics
    Q3 FY2026[1]
  • Other-category segment profit$179M; +34% year over year; includes NPHS, at-Home Solutions and OptiFreight Logistics
    Q3 FY2026[1]
  • Total revenue$222.578B
    FY2025[3]
  • Revenue growth (YoY, derived)-1.9%
    FY2025[3]
  • Gross profit$8.168B
    FY2025[3]
  • GAAP operating earnings$2.275B
    FY2025[3]
  • Diluted EPS$6.45
    FY2025[3]
  • Operating cash flow$2.397B
    FY2025[3]
  • Free cash flow (derived: OCF less capex)$1.850B
    FY2025[3]
  • Capital expenditures$547M
    FY2025[3]
  • Cash and equivalents$3.874B
    FY2025 year-end[3]

Limitation: Net earnings attributable to Cardinal Health, total debt, net debt, net-debt/EBITDA, interest coverage and ROIC are unavailable in the packet's filing evidence and were not independently re-sourced; all market-based valuation multiples (EV/EBITDA, free-cash-flow yield) are unavailable without licensed market data, so valuation cannot be assessed here. Reported margins are thin (gross ~3.7%, operating ~1.0%), consistent with a distribution model.

Risks

Material risks and break conditions

Material risks

  • Structurally thin distribution margins (FY2025 gross margin ~3.7%, operating margin ~1.0%) mean modest generic deflation, branded-mix shifts, or renegotiation with large customers can materially move profit.
  • Customer concentration: a small number of large pharmacy and health-system customers represent a large share of Pharmaceutical segment revenue, creating renewal and pricing risk.
  • Opioid litigation and settlement obligations and other legal reserves represent multi-year cash outflows and residual liability risk.
  • GMPD remains a low-margin, turnaround-sensitive segment exposed to medical-product cost inflation, tariffs and supply-chain disruption.
  • Nuclear/isotope-specific: dependence on Molybdenum-99/Technetium-99m and other isotope supply (aging reactor/cyclotron base), NRC and radiopharmaceutical regulation, reimbursement dynamics, and execution risk on the theranostics build-out that may not convert to profit.

Thesis-break conditions

  • Pharmaceutical and Specialty Solutions segment profit growth turns negative for consecutive quarters, signaling erosion of distribution/generic economics.
  • 'Other'-segment (NPHS et al.) profit growth falls durably below the ~10% normalized long-term target, indicating the nuclear/theranostics thesis is not materializing.
  • A new opioid, regulatory or product-liability charge materially exceeds reserved amounts, impairing free cash flow.
Investability conclusion

Where the evidence lands

Analytically, Cardinal Health pairs defensive, scale-driven distribution cash flows with genuine, issuer-disclosed optionality on the medical-isotope and theranostics logistics theme via the largest US nuclear pharmacy network — a scarce, decay-constrained asset that is hard to replicate. The countervailing facts are a very low-margin model, meaningful customer concentration, and multi-year opioid/legal cash outflows; and the isotope exposure, while strategically real and named in filings, is not separately quantified because NPHS is aggregated within the 'Other' category. Whether the current price fairly reflects these dynamics cannot be judged here because licensed market/valuation data was unavailable. This is an evidence assessment, not trading advice.

Next diligence

  1. Obtain NPHS-level revenue and profit disaggregation (segment supplements, investor-day detail) to quantify the medical-isotope exposure now aggregated within 'Other'.
  2. Review isotope supply agreements and continuity (Mo-99/Tc-99m, Ac-225, PET tracers) and cyclotron-network utilization economics.
  3. Model the opioid settlement cash-outflow schedule and remaining legal reserves against free cash flow.
  4. Acquire licensed market data to compute valuation (EV/EBITDA, FCF yield), net debt and interest coverage.
  5. Track theranostic/radioligand approvals and imaging-volume trends that drive patient-specific dose demand.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises OutlookCardinal Health, Inc. · primary · published 2026-04-30 · accessed 2026-07-29
  2. Cardinal Health expands Actinium-225 production capacityCardinal Health, Inc. · primary · published 2026-04-01 · accessed 2026-07-29
  3. CARDINAL HEALTH INC FY2025 Form 10-K (accession 0000721371-25-000079)U.S. Securities and Exchange Commission (EDGAR) · primary · published 2025-08-12 · accessed 2026-07-22
  4. Investor Day 2025: Momentum, strong performance and multi-year growthCardinal Health (company newsroom) · primary · published 2025-06-25 · accessed 2026-07-22
  5. Nuclear & Precision Health Solutions / Nuclear medicineCardinal Health · primary · published 2025-01-01 · accessed 2026-07-22